NCT04624204 2025-07-02
MK 7339-013
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
Clinical Trials
27 trialsNCT04199689 2025-03-25
V503-049
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT02641639 2025-03-24
FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer
Mateon Therapeutics
Phase 2/3 Terminated
NCT04571645 2024-04-15
AML
Jazz Pharmaceuticals
Phase 3 Terminated
NCT04426201 2024-04-11
ILIAD-7-US-O
Revimmune
Phase 2 Terminated
NCT02258451 2023-11-24
Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer
Bayer
Phase 2 Completed
NCT04262336 2023-07-06
Study to Evaluate Safety and Efficacy of DB-020 to Protect Hearing in Patients Receiving Cisplatin for Cancer Treatment
Decibel Therapeutics
Phase 1 Completed
NCT04863248 2023-04-14
PRESERVE 4
G1 Therapeutics, Inc.
Phase 2 Terminated
NCT04095858 2023-02-08
CATHY
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3 Terminated
NCT03241810 2020-09-02
SHERBOC
Elevation Oncology
Phase 2 Terminated
NCT02258464 2020-08-10
Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer
Bayer
Phase 2 Terminated
NCT00866970 2020-07-09
Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia
CSL Behring
Phase 2 Completed
NCT04026321 2019-07-19
Single-dose Escalation Study of SQ-001 Infusion to Characterize the PK Profiles of Major Sentinel Compounds in Healthy Adult Volunteers in US
Livzon Pharmaceutical Group Inc.
Phase 1 Completed
NCT02889848 2019-07-10
Safety and Tolerability of Collagenase Clostridium Histolyticum (EN3835) to Treat Uterine Leiomyoma (Fibroids)
Advance Biofactures Corporation
Phase 1 Completed
NCT01453153 2018-11-30
Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer
Halozyme Therapeutics
Phase 1/2 Completed
NCT03455205 2018-03-06
Shenqi Fuzheng Injection for the Treatment of Cancer-related Fatigue in Chemo Patients With Digestive Tract .
Livzon Pharmaceutical Group Inc.
Phase NA Unknown
NCT02049151 2017-08-23
START2
EMD Serono
Phase 3 Terminated
NCT03117335 2017-04-17
Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer
Jiangsu Wuzhong Pharmaceutical Group Co., Ltd.
Phase 3 Completed
NCT00854308 2017-03-31
A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)
Genentech, Inc.
Phase 2 Completed
NCT01015443 2016-10-26
INSPIRE
Merck KGaA, Darmstadt, Germany
Phase 3 Terminated
NCT01083615 2016-10-12
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Achieve Life Sciences
Phase 3 Terminated
NCT00960115 2015-10-21
Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy
Merck KGaA, Darmstadt, Germany
Phase 1/2 Completed
NCT00967512 2014-09-18
Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to Frontline Induction Course
Eleos, Inc.
Phase 2 Withdrawn
NCT00925548 2014-07-24
STRIDE
EMD Serono
Phase 3 Terminated
NCT00459654 2014-06-25
A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer
Bayer
Phase 2 Completed
NCT02166554 2014-06-18
BAP
BioRegen Biomedical (CHangzhou) Co., Ltd
Phase 1/2 Completed
NCT00518895 2011-11-07
AGENDA
Genta Incorporated
Phase 3 Completed